Pharmacokinetics: The Foundation of Drug Movement
Pharmacokinetics describes what the body does to a drug. It encompasses the processes of absorption, distribution, metabolism, and excretion. Understanding these processes is fundamental to predicting drug behavior and clinical outcomes.
Absorption and Bioavailability
Absorption refers to the movement of a drug from its administration site into the bloodstream. The rate and extent of absorption depend on factors including route of administration, drug solubility, and gastrointestinal pH.
Bioavailability represents the fraction of an administered dose that reaches systemic circulation unchanged. It is highly dependent on first-pass metabolism, where oral drugs are metabolized by hepatic enzymes before entering general circulation. This process significantly reduces bioavailability for drugs extensively metabolized by the liver.
Distribution and Protein Binding
Distribution describes how drugs spread throughout the body. This process is influenced by lipid solubility, protein binding, and blood flow to tissues. Drugs that are highly protein-bound remain in the bloodstream longer and may displace other bound drugs, creating clinically significant interactions.
Metabolism and the Cytochrome P450 System
Metabolism primarily occurs in the liver through three phases:
- Phase I (oxidation, reduction, hydrolysis)
- Phase II (conjugation)
- Phase III (transport)
The cytochrome P450 enzyme system metabolizes the majority of drugs. Key enzymes include CYP3A4, CYP2D6, and CYP2C9. This system represents a critical source of drug interactions when enzyme induction or inhibition occurs.
Excretion and Elimination
Excretion, predominantly renal, eliminates drugs and metabolites from the body. Understanding clearance and half-life allows prediction of steady-state drug concentrations and appropriate dosing intervals.
Half-life is particularly important clinically. Reaching steady state requires approximately five half-lives of continuous dosing. This concept guides dosing frequency and helps predict when drug levels stabilize.
Pharmacodynamics: Drug-Receptor Interactions and Mechanism of Action
Pharmacodynamics describes what a drug does to the body. This focuses on mechanisms of action and drug-receptor interactions. Most drugs exert therapeutic effects by binding to specific receptors (proteins capable of producing physiological responses upon ligand binding).
Receptor Types and Drug Effects
Agonists bind to receptors and produce effects. Full agonists produce complete response, while partial agonists produce submaximal responses. Antagonists bind to receptors without producing effects and prevent agonist binding. They are classified as competitive (overcome by increased agonist concentration) or non-competitive.
Dose-Response Curves and Drug Potency
The dose-response curve illustrates the relationship between drug dose and effect. Two key measures are:
- EC50: The dose producing 50% of maximal effect. This measures potency (how much drug you need).
- Efficacy: The maximum effect a drug can produce, regardless of dose.
These concepts are distinct. A potent drug requires less dose, but efficacy refers to the ceiling effect the drug can achieve.
Drug-Drug Interactions at the Receptor Level
Drug-drug interactions at the receptor level occur when one drug affects another's ability to bind or signal. Pharmacokinetic interactions involve alterations in absorption, metabolism, or excretion (covered in the first section).
Receptor selectivity determines whether a drug affects desired targets or produces off-target effects. Selective drugs generally produce fewer side effects. Understanding the relationship between receptor occupancy and physiological response allows prediction of therapeutic windows and potential toxicity.
Drug Interactions and Clinical Significance
Drug interactions represent one of the most tested aspects of general pharmacology on USMLE Step 1. These interactions occur when one drug affects another's pharmacokinetics or pharmacodynamics.
Enzyme Induction and Inhibition
Enzyme induction occurs when drugs like rifampin, phenytoin, carbamazepine, and St. John's Wort increase cytochrome P450 activity. This accelerates metabolism of other drugs and potentially reduces their effectiveness. Classic examples include oral contraceptives becoming less effective when co-administered with rifampin, as the antibiotic induces metabolism of estrogen components.
Enzyme inhibition occurs with drugs like ketoconazole, clarithromycin, erythromycin, grapefruit juice, and protease inhibitors. These decrease P450 activity and increase plasma concentrations of substrates, potentially causing toxicity. The interaction between simvastatin and clarithromycin exemplifies this risk, as inhibition can dramatically increase statin levels and cause rhabdomyolysis.
Protein Binding Competition
Competition for protein binding can displace drugs from albumin or other binding sites. This transiently increases free drug concentration and effect. Warfarin interactions with NSAIDs and sulfonamides occur through this mechanism.
Pharmacodynamic Interactions
Pharmacodynamic interactions involve additive, synergistic, or antagonistic effects at the receptor or physiological level. ACE inhibitors and NSAIDs both affect renal hemodynamics. Concurrent use increases hyperkalemia and renal dysfunction risk.
Understanding which drugs compete for the same metabolic pathway or receptor system allows prediction and prevention of clinically significant interactions. This skill is heavily emphasized in pharmacology teaching and testing.
Common Drug Classes and Key Characteristics
Success on USMLE Step 1 pharmacology requires familiarity with major drug classes and their key characteristics, mechanisms, and distinguishing features.
Beta-Blockers and Cardioselective Properties
Beta-blockers represent a foundational class with shared properties including decreased heart rate and blood pressure. However, they differ in receptor selectivity, lipophilicity, and intrinsic sympathomimetic activity.
Propranolol is lipophilic and crosses the blood-brain barrier, causing CNS effects. Atenolol is hydrophilic and renally cleared. Understanding these distinctions allows prediction of individual drug advantages and disadvantages.
Statins and Tissue Distribution
Statins lower cholesterol through HMG-CoA reductase inhibition. Lipophilic agents like simvastatin penetrate tissues better than hydrophilic pravastatin. This creates different drug interaction profiles and tissue distribution patterns.
Antihypertensive Drug Classes
ACE inhibitors and angiotensin II receptor blockers represent important antihypertensive classes with different mechanisms but similar clinical effects and contraindications. ACE inhibitors cause a characteristic dry cough through bradykinin accumulation. ARBs typically do not cause this side effect.
Antidepressants and P450 Interactions
Selective serotonin reuptake inhibitors revolutionized depression treatment but vary significantly in cytochrome P450 interactions. Fluoxetine and paroxetine are strong inhibitors, while sertraline is mild. These distinctions create different drug-drug interaction profiles critical for clinical practice.
Fluoroquinolones and Toxicity Risks
Fluoroquinolones possess broad-spectrum antibacterial activity but share toxicity risks including tendon rupture and QT prolongation. Studying drugs within classes emphasizes shared mechanisms while appreciating important individual differences. This approach is well-suited to flashcard learning.
Special Populations and Pharmacological Considerations
USMLE Step 1 emphasizes understanding how pharmacokinetics and pharmacodynamics differ in special populations. These groups include pediatric patients, elderly patients, pregnant women, and those with hepatic or renal disease.
Pediatric Patients and Immature Metabolism
Pediatric patients require dose adjustments because body composition, hepatic enzyme maturity, and renal function differ substantially from adults. Neonates have immature Phase II hepatic conjugation enzymes. This leads to reduced metabolism of drugs like acetaminophen and requires extended dosing intervals.
Elderly Patients and Reduced Clearance
The elderly demonstrate altered pharmacokinetics due to decreased hepatic metabolism, reduced renal clearance, and changes in body composition. They have increased adipose tissue and decreased total body water. These changes necessitate lower doses and extended intervals to prevent toxicity.
Pregnant Women and Placental Transfer
Pregnancy creates unique pharmacological challenges as drugs cross the placenta and may affect fetal development. FDA pregnancy categories (now replaced by narrative summaries) historically guided prescribing. Category A drugs were considered safest, while Category X drugs were absolutely contraindicated.
Hepatic and Renal Disease
Hepatic disease impairs drug metabolism, particularly affecting drugs with high hepatic extraction ratios. It requires dose reduction for many medications. Renal disease eliminates renally cleared drugs and their metabolites. Dose adjustments are based on creatinine clearance calculated using the Cockcroft-Gault equation.
Understanding how to adjust doses in these populations involves calculating renal function, estimating pharmacokinetic parameters, and recognizing drugs requiring particular caution. This knowledge frequently appears in clinical vignette questions.